• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    National Vision Holdings, Inc. Reports Second Quarter 2023 Financial Results

    8/10/23 6:00:00 AM ET
    $EYE
    Ophthalmic Goods
    Health Care
    Get the next $EYE alert in real time by email
    • Net revenue of $525.3 million, an increase of 3.1% from Q2 2022
    • Comparable store sales growth of (0.1%) and Adjusted Comparable Store Sales Growth of 1.0% from Q2 2022
    • Net income of $5.6 million and Diluted EPS of $0.07 compared with $9.7 million and $0.12, respectively in Q2 2022
    • Adjusted Operating Income of $16.4 million compared with $27.8 million in Q2 2022
    • Adjusted Diluted EPS of $0.17 compared with $0.21 in Q2 2022

    National Vision Holdings, Inc. (NASDAQ:EYE) ("National Vision" or the "Company") today reported its financial results for the second quarter ended July 1, 2023.

    "We delivered second quarter 2023 results generally in line with our expectations, reflecting continued strength in our managed care business and progress on our strategic initiatives, including expanding exam capacity through enhanced optometrist retention and recruitment efforts," said Reade Fahs, National Vision's CEO. "As we look ahead, we remain focused on better serving our customers, enhancing our market position and driving long-term growth of our America's Best and Eyeglass World brands. While we continue to navigate near-term headwinds, we believe National Vision remains well positioned to achieve our full-year 2023 guidance and deliver sustainable profitable growth over the long term."

    This release includes certain Non-GAAP Financial Measures that are not recognized under generally accepted accounting principles ("GAAP"). Please see "Non-GAAP Financial Measures" and "Reconciliation of Non-GAAP to GAAP Financial Measures" below for more information.

    Second Quarter 2023 Summary

    • Net revenue increased 3.1% to $525.3 million compared with the second quarter of 2022 primarily due to growth from new store sales and an increase in Adjusted Comparable Store Sales Growth, partially offset by the effect of unearned revenue in the second quarter of 2023 compared with the prior-year quarter. Net revenue includes a (0.9%) impact from the timing of unearned revenue in the current-year quarter compared with the prior-year quarter.
    • Comparable store sales growth was (0.1%) and Adjusted Comparable Store Sales Growth was 1.0%, both reflecting higher average ticket and an increase in customer transactions. Comparable store sales growth was negatively impacted by the effects of unearned and deferred revenue in the current-year quarter compared with the prior-year quarter.
    • The Company opened 24 new stores, closed one store, and ended the quarter with 1,381 stores. Overall, store count grew 5.1% from July 2, 2022 to July 1, 2023.
    • Costs applicable to revenue increased 5.7% to $247.8 million compared with the second quarter of 2022. As a percentage of net revenue, costs applicable to revenue increased 120 basis points to 47.2% compared with the second quarter of 2022 and were primarily driven by an increase in optometrist-related costs partially offset by increased exam revenue. In addition, costs applicable to revenue as a percentage of net revenue increased due to lower product protection plan revenue as well as other product mix and margin effects.
    • Selling, general and administrative expenses (SG&A) increased 7.1% to $244.0 million compared with the second quarter of 2022. Adjusted SG&A increased 6.3% to $238.0 million compared with the second quarter of 2022. As a percentage of net revenue, SG&A increased 170 basis points to 46.4% compared with the second quarter of 2022 mainly due to increases in performance-based incentive and stock-based compensation, payroll, and occupancy expense offset primarily by a decrease in other expenses. As a percentage of net revenue, adjusted SG&A increased 140 basis points to 45.3% compared with the second quarter of 2022, driven by increases in payroll, performance-based incentive compensation, and occupancy expense, partially offset by a decrease in other expenses.
    • Depreciation and amortization expense of $24.9 million decreased 1.3% from the prior-year period primarily due to a shift to cloud-based software investments that are amortized in SG&A, partially offset by the Company's ongoing investments in remote medicine technology and new store openings.
    • Net income decreased 42.3% to $5.6 million compared with the second quarter of 2022. Net income margin decreased 80 basis points to 1.1% compared with the second quarter of 2022.
    • Diluted earnings per share (EPS) decreased 40.8% to $0.07 compared with the second quarter of 2022. Adjusted Diluted EPS decreased 19.1% to $0.17 compared with the second quarter of 2022. The change in margin on unearned revenue negatively impacted Diluted EPS by $0.03 and Adjusted Diluted EPS by $0.03.
    • Adjusted Operating Income decreased 40.8% to $16.4 million compared with the second quarter of 2022. Adjusted Operating Margin decreased 240 basis points to 3.1% compared with the second quarter of 2022. The change in margin on unearned revenue negatively impacted net income by $2.6 million and Adjusted Operating Income by $3.5 million.

    Six Months Year-to-Date Summary

    • Net revenue increased 4.9% to $1,087.7 million compared with the same period of 2022 and was primarily driven by growth from new store sales, an increase in Adjusted Comparable Store Sales Growth, higher revenue from the Company's AC Lens business and the effect of unearned revenue in the current period compared with the prior-year period. Net revenue includes a 0.6% impact from the timing of unearned revenue in the current-year period compared with the prior-year period.
    • Comparable store sales growth was 1.5% and Adjusted Comparable Store Sales Growth was 0.9%, both reflecting higher average ticket and an increase in customer transactions.
    • The Company opened 32 new stores, closed six stores, and ended the period with 1,381 stores.
    • Costs applicable to revenue increased 6.6% to $501.9 million compared with the same period in 2022. As a percentage of net revenue, compared with the prior-year period, costs applicable to revenue increased 70 basis points to 46.1%, mainly due to an increase in optometrist-related costs partially offset by increased exam revenue and the effects from increased eyeglass mix and higher eyeglass margin. In addition, costs applicable to revenue as a percentage of net revenue increased due to lower product protection plan revenue.
    • SG&A increased 8.2% to $493.9 million compared with the same period in 2022. Adjusted SG&A increased 8.2% to $483.6 million compared with the same period of 2022. As a percentage of net revenue, SG&A increased 140 basis points to 45.4% compared with the same period in 2022 mainly due to increases in performance-based incentive and stock-based compensation and payroll, partially offset by lower advertising expense. As a percentage of net revenue, adjusted SG&A increased 140 basis points driven by increases in performance-based incentive compensation and payroll, partially offset by lower advertising expense​.
    • Depreciation and amortization expense of $49.7 million decreased 1.3% from the prior-year period primarily due to a shift to cloud-based software investments that are amortized in SG&A, partially offset by the Company's ongoing investments in remote medicine technology and new store openings.
    • Net income decreased 40.1% to $23.9 million compared with the same period in 2022. Net income margin decreased 160 basis points to 2.2% compared with the same period in 2022.
    • Diluted EPS decreased 36.0% to $0.30 compared to the same period in 2022. Adjusted Diluted EPS decreased 4.4% to $0.51 compared to the same period in 2022. The net change in margin on unearned revenue benefited Diluted EPS by $0.04 and Adjusted Diluted EPS by $0.04.
    • Adjusted Operating Income decreased 22.9% to $56.3 million compared with the same period of 2022. Adjusted Operating Margin decreased 180 basis points to 5.2% compared with the same period in 2022. The net change in margin on unearned revenue benefited net income by $3.5 million and Adjusted Operating Income by $4.7 million.

    Balance Sheet and Cash Flow Highlights as of July 1, 2023

    • National Vision's cash balance was $254.6 million as of July 1, 2023. The Company had no borrowings under its $300.0 million first-lien revolving-credit facility ("Revolving Loans"), exclusive of letters of credit of $6.4 million.
    • Total debt was $565.7 million as of July 1, 2023, consisting of outstanding first-lien term loans, convertible senior notes ("2025 Notes") and finance lease obligations, net of unamortized discounts.
    • Cash flows from operating activities for the first six months of 2023 were $112.2 million compared to $88.0 million for the second quarter of 2022. The year-over-year increase was primarily due to timing of incentive compensation-related payments.
    • Capital expenditures for the first six months of 2023 totaled $54.1 million compared to $55.7 million for the second quarter of 2022.
    • As previously announced in June 2023, National Vision entered into an amended credit agreement, extending its access to $300.0 million in liquidity through Revolving Loans for an additional five years through June 13, 2028.

    Share Repurchase Program

    In the second quarter of 2023, the Company did not repurchase any shares of its common stock. Year to date through July 1, 2023, National Vision repurchased approximately 1.1 million shares for $25.0 million. The Company has $25.0 million remaining under its current share repurchase authorization.

    Recent Development

    As previously announced on July 26, 2023, the Company's partnership with Walmart Inc. ("Walmart") will be ending in 2024. This includes supplying and operating Vision Centers in select Walmart stores, providing contact lens distribution and related services to Walmart and its affiliate, and arranging for the provision of optometric services at certain Walmart locations in California. In connection with the termination of these agreements, National Vision expects to record noncash goodwill and intangible asset impairment charges of approximately $60 million and $10 million, respectively, in the third quarter of 2023.

    Fiscal 2023 Outlook

    National Vision's fiscal 2023 outlook reflects current expected or estimated impacts related to macro-economic factors, including inflation, geopolitical instability and risks of recession, as well as constraints on exam capacity; however, the ultimate impact of these factors on the Company's financial outlook remains uncertain with dynamic market conditions and the outlook shown below assumes no material deterioration to the Company's current business operations as a result of such factors or as a result of the termination of the Walmart partnership.

    Based on its financial results for the six months ended July 1, 2023, and outlook for the remainder of this fiscal year, National Vision is reaffirming its fiscal-2023 guidance as provided on May 11, 2023 for all metrics except for depreciation and amortization, which the Company now expects to be in a range of $99 million to $101 million from the previous range of $104 million to $106 million. National Vision also noted that based on its year-to-date performance, it expects Adjusted Operating Income and Adjusted Diluted EPS to be at or above the midpoint of its fiscal 2023 guidance range.

    Guidance Metric

    Fiscal-2023 Guidance Range (as of August 10, 2023)

    New Stores

    65 to 70

    Adjusted Comparable Store Sales Growth

    0% to 3%

    Net Revenue

    $2.075 billion to $2.135 billion

    Adjusted Operating Income

    $48 million to $66 million

    Adjusted Diluted EPS1

    $0.42 to $0.60

    Depreciation and Amortization2

    $99 million to $101 million (previously: $104 million to $106 million)

    Interest3

    ~$3 million

    Tax Rate4

    26% to 28%

    Capital Expenditures

    $115 million to $120 million

     

     

    1 Assumes approximately 79 million shares and does not include 12.9 million shares attributable to the 2025 Notes and shares from stock-based compensation awards as the company anticipates them to be anti-dilutive to earnings per share for fiscal year 2023.

    2 Includes amortization of acquisition intangibles of approximately $4.5 million, which is excluded in the definition of Adjusted Operating Income and reflects the anticipated impact of the intangible asset impairment in connection with the termination of the Walmart agreements.

    3 Before the impact of gains or losses on change in fair value of derivatives and charges related to amortization of debt discounts and deferred financing costs.

    4 Excluding the impact of vesting of restricted stock units and stock option exercises.

    The fiscal 2023 outlook information provided above includes Adjusted Operating Income and Adjusted Diluted EPS guidance, which are non-GAAP financial measures management uses in measuring performance. The Company is not able to reconcile these forward-looking non-GAAP measures to GAAP without unreasonable efforts because it is not possible to predict with a reasonable degree of certainty the actual impact of certain items and unanticipated events, including taxes and non-recurring items, which would be included in GAAP results. The impact of such items and unanticipated events could be potentially significant.

    The fiscal 2023 outlook is forward-looking, subject to significant business, economic, regulatory and competitive uncertainties and contingencies, many of which are beyond the control of the Company and its management, and based upon assumptions with respect to future decisions, which are subject to change. Actual results may vary and those variations may be material. As such, the Company's results may not fall within the ranges contained in its fiscal 2023 outlook. The Company uses these forward-looking measures internally to assess and benchmark its results and strategic plans. See "Forward-Looking Statements" below.

    Conference Call Details

    The Company will host a conference call to discuss its second quarter 2023 financial results and fiscal-year 2023 guidance today, August 10, 2023, at 8:30 a.m. Eastern Time. To pre-register for the conference call and obtain a dial-in number and passcode please refer to the "Investors" section of the Company's website at www.nationalvision.com/investors. A live audio webcast of the conference call will be available on the "Investors" section of the Company's website at www.nationalvision.com/investors, where presentation materials will be posted prior to the conference call. A replay of the audio webcast will also be archived on the "Investors" section of the Company's website.

    About National Vision Holdings, Inc.

    National Vision Holdings, Inc. is the second largest optical retail company in the United States (by sales) with more than 1,300 retail stores in 44 states and Puerto Rico. With a mission of helping people by making quality eye care and eyewear more affordable and accessible, the Company operates five retail brands: America's Best Contacts & Eyeglasses, Eyeglass World, Vision Centers inside select Walmart stores, and Vista Opticals inside select Fred Meyer stores and on select military bases, and several e-commerce websites, offering a variety of products and services for customers' eye care needs.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934. These statements include, but are not limited to, statements contained under "Recent Development" and "Fiscal 2023 Outlook" as well as other statements related to our current beliefs and expectations regarding the performance of our industry, the Company's strategic direction, market position, prospects including remote medicine and optometrist recruiting and retention initiatives, and future results. You can identify these forward-looking statements by the use of words such as "outlook," "guidance," "believes," "expects," "potential," "continues," "may," "will," "should," "could," "seeks," "projects," "predicts," "intends," "plans," "estimates," "anticipates" or the negative version of these words or other comparable words. Caution should be taken not to place undue reliance on any forward-looking statement as such statements speak only as of the date when made. We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law. Forward-looking statements are not guarantees and are subject to various risks and uncertainties, which may cause actual results to differ materially from those implied in forward-looking statements. Such factors include, but are not limited to, the COVID-19 pandemic and future resurgences, and related impacts including federal, state, and local governmental actions in response thereto; customer behavior in response to the pandemic, including the impact of such behavior on in-store traffic and sales; market volatility and an overall decline in the health of the economy and other factors impacting consumer spending, including inflation and uncertainty in financial markets (including as a result of recent bank failures and events affecting financial institutions); our ability to recruit and retain vision care professionals for our stores and remote medicine offerings in general and in light of the pandemic; our ability to compete successfully; our ability to successfully open new stores and enter new markets; our ability to expand our remote medicine offerings and electronic health records capabilities; our ability to maintain the performance of our Host and Legacy brands and our current operating relationships with our Host and Legacy partners; our ability to successfully navigate the termination of our Walmart partnership, including the transition period; our ability to maintain sufficient levels of cash flow from our operations to execute or sustain our growth strategy or obtain additional financing at satisfactory terms or at all; the impact of wage rate increases, inflation, cost increases and increases in raw material prices and energy prices; our growth strategy straining our existing resources and causing the performance of our existing stores to suffer; our ability to successfully and efficiently implement our marketing, advertising and promotional efforts; risks associated with leasing substantial amounts of space, including future increases in occupancy costs; the impact of certain technological advances, and the greater availability of, or increased consumer preferences for, vision correction alternatives to prescription eyeglasses or contact lenses, and future drug development for the correction of vision-related problems; our ability to retain our existing senior management team and attract qualified new personnel; our ability to manage our inventory; seasonal fluctuations in our operating results and inventory levels; risks associated with our e-commerce and omni-channel business; the loss of, or disruption in the operations of, one or more of our distribution centers and/or optical laboratories, resulting in the inability to fulfill customer orders and deliver our products in a timely manner; risk of losses arising from our investments in technological innovators in the optical retail industry; risks associated with environmental, social and governance issues, including climate change; risks associated with vendors from whom our products are sourced, including our dependence on a limited number of suppliers; our ability to develop, maintain and extend relationships with managed vision care companies, vision insurance providers and other third-party payors; our ability to effectively operate our information technology systems and prevent interruption or security breach; our reliance on third-party coverage and reimbursement, including government programs, for an increasing portion of our revenues; our ability to adhere to extensive state, local and federal vision care and healthcare laws and regulations; our compliance with managed vision care laws and regulations; our ability to adhere to changing state, local and federal privacy, data security and data protection laws and regulations; product liability, product recall or personal injury issues; our failure to comply with, or changes in, laws, regulations, enforcement activities and other requirements; the impact of any adverse litigation judgments or settlements resulting from legal proceedings relating to our business operations; our ability to adequately protect our intellectual property; our significant amount of indebtedness and our ability to generate sufficient cash flow to satisfy our debt obligations; a change in interest rates as well as changes in benchmark rates and uncertainty related to the foregoing; restrictions in our credit agreement that limits our flexibility in operating our business; potential dilution to existing stockholders upon the conversion of our convertible notes; and risks related to owning our common stock (including the timing, manner and volume of repurchases of common stock pursuant to our share repurchase program), including our ability to comply with requirements to design and implement and maintain effective internal controls. Additional information about these and other factors that could cause National Vision's results to differ materially from those described in the forward-looking statements can be found in filings by National Vision with the Securities and Exchange Commission ("SEC"), including our latest Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, which are accessible on the SEC's website at www.sec.gov. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this release and in our filings with the SEC.

    Non-GAAP Financial Measures

    To supplement the Company's financial information presented in accordance with GAAP and aid understanding of the Company's business performance, the Company uses certain non-GAAP financial measures, namely "EBITDA," "Adjusted Operating Income," "Adjusted Operating Margin," "Adjusted EBITDA," "Adjusted EBITDA Margin," "Adjusted Diluted EPS," "Adjusted Comparable Stores Sales Growth," "Adjusted SG&A," and "Adjusted SG&A Percent of Net Revenue." We believe EBITDA, Adjusted Operating Income, Adjusted Operating Margin, Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Diluted EPS, Adjusted SG&A and Adjusted SG&A Percent of Net Revenue assist investors and analysts in comparing our operating performance across reporting periods on a consistent basis by excluding items that we do not believe are indicative of our core operating performance. Management believes these non-GAAP financial measures are useful to investors in highlighting trends in our operating performance, while other measures can differ significantly depending on long-term strategic decisions regarding capital structure, the tax jurisdictions in which we operate and capital investments. Management uses these non-GAAP financial measures to supplement GAAP measures of performance in the evaluation of the effectiveness of our business strategies, to make budgeting decisions, to establish discretionary annual incentive compensation and to compare our performance against that of other peer companies using similar measures. Management supplements GAAP results with non-GAAP financial measures to provide a more complete understanding of the factors and trends affecting the business than GAAP results alone.

    To supplement the Company's comparable store sales growth presented in accordance with GAAP, the Company provides "Adjusted Comparable Store Sales Growth," which is a non-GAAP financial measure we believe is useful because it provides timely and accurate information relating to the two core metrics of retail sales: number of transactions and value of transactions. Management uses Adjusted Comparable Store Sales Growth as the basis for key operating decisions, such as allocation of advertising to particular markets and implementation of special marketing programs. Accordingly, we believe that Adjusted Comparable Store Sales Growth provides timely and accurate information relating to the operational health and overall performance of each brand. We also believe that, for the same reasons, investors find our calculation of Adjusted Comparable Store Sales Growth to be meaningful.

    EBITDA: We define EBITDA as net income, plus interest expense (income), net, income tax provision (benefit), and depreciation and amortization.

    Adjusted Operating Income: We define Adjusted Operating Income as net income, plus interest expense (income), net and income tax provision (benefit), further adjusted to exclude stock-based compensation expense, loss on extinguishment of debt, asset impairment, litigation settlement, secondary offering expenses, management realignment expenses, long-term incentive plan expenses, amortization of acquisition intangibles, and certain other expenses.

    Adjusted Operating Margin: We define Adjusted Operating Margin as Adjusted Operating Income as a percentage of net revenue.

    Adjusted EBITDA: We define Adjusted EBITDA as net income, plus interest expense (income), net, income tax provision (benefit) and depreciation and amortization, further adjusted to exclude stock-based compensation expense, loss on extinguishment of debt, asset impairment, litigation settlement, secondary offering expenses, management realignment expenses, long-term incentive plan expenses, and certain other expenses.

    Adjusted EBITDA Margin: We define Adjusted EBITDA Margin as Adjusted EBITDA as a percentage of net revenue.

    Adjusted Diluted EPS: We define Adjusted Diluted EPS as diluted earnings per share, adjusted for the per share impact of stock-based compensation expense, loss on extinguishment of debt, asset impairment, litigation settlement, secondary offering expenses, management realignment expenses, long-term incentive plan expenses, amortization of acquisition intangibles, amortization of debt discounts and deferred financing costs of the term loan borrowings, amortization of the conversion feature and deferred financing costs related to the 2025 Notes when not required under U.S. GAAP to be added back for diluted earnings per share, losses (gains) on change in fair value of derivatives, certain other expenses, and tax expense (benefit) from stock-based compensation, less the tax effect of these adjustments.

    Adjusted SG&A: We define Adjusted SG&A as SG&A, adjusted to exclude stock-based compensation expense, litigation settlement, secondary offering expenses, management realignment expenses, long-term incentive plan expense, and certain other expenses.

    Adjusted SG&A Percent of Net Revenue: We define Adjusted SG&A Percent of Net Revenue as Adjusted SG&A as a percentage of net revenue.

    Adjusted Comparable Store Sales Growth: We measure Adjusted Comparable Store Sales Growth as the increase or decrease in sales recorded by the comparable store base in any reporting period, compared to sales recorded by the comparable store base in the prior reporting period, which we calculate as follows: (i) sales are recorded on a cash basis (i.e. when the order is placed and paid for or submitted to a managed care payor, compared to when the order is delivered), utilizing cash basis point of sale information from stores; (ii) stores are added to the calculation during the 13th full fiscal month following the store's opening; (iii) closed stores are removed from the calculation for time periods that are not comparable; (iv) sales from partial months of operation are excluded when stores do not open or close on the first day of the month; and (v) when applicable, we adjust for the effect of the 53rd week. Quarterly, year-to-date and annual adjusted comparable store sales are aggregated using only sales from all whole months of operation included in both the current reporting period and the prior reporting period. When a partial month is excluded from the calculation, the corresponding month in the subsequent period is also excluded from the calculation. There may be variations in the way in which some of our competitors and other retailers calculate comparable store sales. As a result, our adjusted comparable store sales may not be comparable to similar data made available by other retailers.

    EBITDA, Adjusted Operating Income, Adjusted Operating Margin, Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Diluted EPS, Adjusted SG&A, Adjusted SG&A Percent of Net Revenue and Adjusted Comparable Store Sales Growth are not recognized terms under U.S. GAAP and should not be considered as an alternative to net income or the ratio of net income to net revenue as a measure of financial performance, SG&A, the ratio of SG&A to net revenue as a measure of financial performance, cash flows provided by operating activities as a measure of liquidity, comparable store sales growth as a measure of operating performance, or any other performance measure derived in accordance with U.S. GAAP. Additionally, these measures are not intended to be a measure of free cash flow available for management's discretionary use as they do not consider certain cash requirements such as interest payments, tax payments and debt service requirements. The presentations of these measures have limitations as analytical tools and should not be considered in isolation, or as a substitute for analysis of our results as reported under U.S. GAAP. Because not all companies use identical calculations, the presentations of these measures may not be comparable to other similarly titled measures of other companies and can differ significantly from company to company.

    Please see "Reconciliation of Non-GAAP to GAAP Financial Measures" below for reconciliations of non-GAAP financial measures used in this release to their most directly comparable GAAP financial measures.

     

    National Vision Holdings, Inc. and Subsidiaries

    Condensed Consolidated Balance Sheets

    In Thousands, Except Par Value

    (Unaudited)

     

     

    As of

    July 1, 2023

     

    As of

    December 31, 2022

    ASSETS

     

     

     

    Current assets:

     

     

     

    Cash and cash equivalents

    $

    254,647

     

     

    $

    229,425

     

    Accounts receivable, net

     

    78,904

     

     

     

    79,892

     

    Inventories

     

    120,871

     

     

     

    123,158

     

    Prepaid expenses and other current assets

     

    39,865

     

     

     

    41,361

     

    Total current assets

     

    494,287

     

     

     

    473,836

     

     

     

     

     

    Noncurrent assets:

     

     

     

    Property and equipment, net

     

    367,333

     

     

     

    359,775

     

    Goodwill

     

    777,613

     

     

     

    777,613

     

    Trademarks and trade names

     

    240,547

     

     

     

    240,547

     

    Other intangible assets, net

     

    30,900

     

     

     

    34,669

     

    Right of use assets

     

    398,469

     

     

     

    382,825

     

    Other assets

     

    24,779

     

     

     

    21,981

     

    Total noncurrent assets

     

    1,839,641

     

     

     

    1,817,410

     

    Total assets

    $

    2,333,928

     

     

    $

    2,291,246

     

     

     

     

     

    LIABILITIES AND STOCKHOLDERS' EQUITY

     

     

     

    Current liabilities:

     

     

     

    Accounts payable

    $

    64,108

     

     

    $

    65,276

     

    Other payables and accrued expenses

     

    112,946

     

     

     

    94,225

     

    Unearned revenue

     

    39,818

     

     

     

    41,239

     

    Deferred revenue

     

    64,101

     

     

     

    62,201

     

    Current maturities of long-term debt and finance lease obligations

     

    10,501

     

     

     

    4,137

     

    Current operating lease obligations

     

    71,759

     

     

     

    77,186

     

    Total current liabilities

     

    363,233

     

     

     

    344,264

     

     

     

     

     

    Noncurrent liabilities:

     

     

     

    Long-term debt and finance lease obligations, less current portion and debt discount

     

    555,182

     

     

     

    563,388

     

    Noncurrent operating lease obligations

     

    380,675

     

     

     

    358,110

     

    Deferred revenue

     

    21,946

     

     

     

    21,601

     

    Other liabilities

     

    9,261

     

     

     

    8,900

     

    Deferred income taxes, net

     

    95,219

     

     

     

    93,870

     

    Total non-current liabilities

     

    1,062,283

     

     

     

    1,045,869

     

    Commitments and contingencies

     

     

     

    Stockholders' equity:

     

     

     

    Common stock, $0.01 par value; 200,000 shares authorized; 84,625 and 84,273 shares issued as of July 1, 2023 and December 31, 2022, respectively; 78,154 and 78,992 shares outstanding as of July 1, 2023 and December 31, 2022, respectively

     

    846

     

     

     

    842

     

    Additional paid-in capital

     

    777,762

     

     

     

    767,112

     

    Accumulated other comprehensive loss

     

    (801

    )

     

     

    (1,179

    )

    Retained earnings

     

    344,401

     

     

     

    320,517

     

    Treasury stock, at cost; 6,471 and 5,281 shares as of July 1, 2023 and December 31, 2022, respectively

     

    (213,796

    )

     

     

    (186,179

    )

    Total stockholders' equity

     

    908,412

     

     

     

    901,113

     

    Total liabilities and stockholders' equity

    $

    2,333,928

     

     

    $

    2,291,246

     

     

    National Vision Holdings, Inc. and Subsidiaries

    Condensed Consolidated Statements of Operations and Comprehensive Income

    In Thousands, Except Earnings Per Share

    (Unaudited)

     

     

    Three Months Ended

     

    Six Months Ended

     

    July 1, 2023

     

    July 2, 2022

     

    July 1, 2023

     

    July 2, 2022

    Revenue:

     

     

     

     

     

     

     

    Net product sales

    $

    432,925

     

     

    $

    421,600

     

    $

    897,686

     

     

    $

    854,853

     

    Net sales of services and plans

     

    92,415

     

     

     

    87,955

     

     

    190,023

     

     

     

    182,413

     

    Total net revenue

     

    525,340

     

     

     

    509,555

     

     

    1,087,709

     

     

     

    1,037,266

     

    Costs applicable to revenue (exclusive of depreciation and amortization):

     

     

     

     

     

     

     

    Products

     

    167,514

     

     

     

    163,361

     

     

    340,616

     

     

     

    327,580

     

    Services and plans

     

    80,325

     

     

     

    71,206

     

     

    161,275

     

     

     

    143,024

     

    Total costs applicable to revenue

     

    247,839

     

     

     

    234,567

     

     

    501,891

     

     

     

    470,604

     

    Operating expenses:

     

     

     

     

     

     

     

    Selling, general and administrative expenses

     

    243,971

     

     

     

    227,829

     

     

    493,893

     

     

     

    456,383

     

    Depreciation and amortization

     

    24,929

     

     

     

    25,245

     

     

    49,742

     

     

     

    50,396

     

    Asset impairment

     

    893

     

     

     

    3,509

     

     

    1,280

     

     

     

    3,915

     

    Other expense (income), net

     

    (17

    )

     

     

    34

     

     

    (134

    )

     

     

    265

     

    Total operating expenses

     

    269,776

     

     

     

    256,617

     

     

    544,781

     

     

     

    510,959

     

    Income from operations

     

    7,725

     

     

     

    18,371

     

     

    41,037

     

     

     

    55,703

     

    Interest expense (income), net

     

    1,836

     

     

     

    3,963

     

     

    6,703

     

     

     

    (181

    )

    Earnings before income taxes

     

    5,889

     

     

     

    14,408

     

     

    34,334

     

     

     

    55,884

     

    Income tax provision

     

    275

     

     

     

    4,674

     

     

    10,450

     

     

     

    16,003

     

    Net income

    $

    5,614

     

     

    $

    9,734

     

    $

    23,884

     

     

    $

    39,881

     

     

     

     

     

     

     

     

     

    Earnings per share:

     

     

     

     

     

     

     

    Basic

    $

    0.07

     

     

    $

    0.12

     

    $

    0.30

     

     

    $

    0.49

     

    Diluted

    $

    0.07

     

     

    $

    0.12

     

    $

    0.30

     

     

    $

    0.47

     

    Weighted average shares outstanding:

     

     

     

     

     

     

     

    Basic

     

    78,101

     

     

     

    80,061

     

     

    78,411

     

     

     

    80,744

     

    Diluted

     

    78,343

     

     

     

    80,403

     

     

    78,784

     

     

     

    94,109

     

     

     

     

     

     

     

     

     

    Comprehensive income:

     

     

     

     

     

     

     

    Net income

    $

    5,614

     

     

    $

    9,734

     

    $

    23,884

     

     

    $

    39,881

     

    Unrealized gain on hedge instruments

     

    255

     

     

     

    255

     

     

    508

     

     

     

    507

     

    Tax provision of unrealized gain on hedge instruments

     

    65

     

     

     

    65

     

     

    130

     

     

     

    129

     

    Comprehensive income

    $

    5,804

     

     

    $

    9,924

     

    $

    24,262

     

     

    $

    40,259

     

    Note: Diluted EPS for the six months ended July 2, 2022 is calculated using the if-converted method for the 2025 Notes. The Company added back $4.7 million in interest expense (after tax) related to the 2025 Notes and assumed conversion of the 2025 Notes at the beginning of the period.

     

    National Vision Holdings, Inc. and Subsidiaries

    Condensed Consolidated Statements of Cash Flows

    In Thousands

    (Unaudited)

     

     

    Six Months Ended

     

    July 1, 2023

     

    July 2, 2022

    Cash flows from operating activities:

     

     

     

    Net income

    $

    23,884

     

     

    $

    39,881

     

    Adjustments to reconcile net income to net cash provided by operating activities:

     

     

     

    Depreciation and amortization

     

    49,742

     

     

     

    50,396

     

    Amortization of debt discount and deferred financing costs

     

    1,800

     

     

     

    1,584

     

    Asset impairment

     

    1,280

     

     

     

    3,915

     

    Deferred income tax expense (benefit)

     

    1,220

     

     

     

    3,512

     

    Stock-based compensation expense

     

    9,788

     

     

     

    7,372

     

    Losses (gains) on change in fair value of derivatives

     

    (1,750

    )

     

     

    (10,745

    )

    Inventory adjustments

     

    1,996

     

     

     

    1,429

     

    Other

     

    1,509

     

     

     

    2,455

     

    Changes in operating assets and liabilities:

     

     

     

    Accounts receivable

     

    560

     

     

     

    (8,661

    )

    Inventories

     

    290

     

     

     

    (7,253

    )

    Operating lease right of use assets and lease liabilities

     

    525

     

     

     

    568

     

    Other assets

     

    3,528

     

     

     

    2,246

     

    Accounts payable

     

    (1,168

    )

     

     

    5,669

     

    Deferred and unearned revenue

     

    824

     

     

     

    3,253

     

    Other liabilities

     

    18,188

     

     

     

    (7,590

    )

    Net cash provided by operating activities

     

    112,216

     

     

     

    88,031

     

    Cash flows from investing activities:

     

     

     

    Purchase of property and equipment

     

    (54,120

    )

     

     

    (55,714

    )

    Other

     

    (665

    )

     

     

    20

     

    Net cash used for investing activities

     

    (54,785

    )

     

     

    (55,694

    )

    Cash flows from financing activities:

     

     

     

    Repayments on long-term debt

     

    —

     

     

     

    (4

    )

    Proceeds from issuance of common stock

     

    945

     

     

     

    2,246

     

    Purchase of treasury stock

     

    (27,611

    )

     

     

    (83,632

    )

    Payments of debt issuance costs

     

    (2,869

    )

     

     

    —

     

    Payments on finance lease obligations

     

    (2,536

    )

     

     

    (2,218

    )

    Net cash used for financing activities

     

    (32,071

    )

     

     

    (83,608

    )

    Net change in cash, cash equivalents and restricted cash

     

    25,360

     

     

     

    (51,271

    )

    Cash, cash equivalents and restricted cash, beginning of year

     

    230,624

     

     

     

    306,876

     

    Cash, cash equivalents and restricted cash, end of period

    $

    255,984

     

     

    $

    255,605

     

     

     

     

     

    Supplemental cash flow disclosure information:

     

     

     

    Cash paid for interest

    $

    5,399

     

     

    $

    9,329

     

    Cash paid for taxes

    $

    4,347

     

     

    $

    5,632

     

    Capital expenditures accrued at the end of the period

    $

    10,770

     

     

    $

    9,300

     

    National Vision Holdings, Inc. and Subsidiaries

    Reconciliation of Non-GAAP to GAAP Financial Measures

    In Thousands, Except Earnings Per Share

    (Unaudited)

    Reconciliation of Adjusted Operating Income to Net Income

     

    Three Months Ended

     

    Six Months Ended

    In thousands

    July 1, 2023

     

    July 2, 2022

     

    July 1, 2023

     

    July 2, 2022

    Net income

    $

    5,614

     

     

    $

    9,734

     

     

    $

    23,884

     

     

    $

    39,881

     

    Interest expense (income), net

     

    1,836

     

     

     

    3,963

     

     

     

    6,703

     

     

     

    (181

    )

    Income tax provision

     

    275

     

     

     

    4,674

     

     

     

    10,450

     

     

     

    16,003

     

    Stock-based compensation expense (a)

     

    5,473

     

     

     

    3,638

     

     

     

    9,788

     

     

     

    7,372

     

    Asset impairment (b)

     

    893

     

     

     

    3,509

     

     

     

    1,280

     

     

     

    3,915

     

    Amortization of acquisition intangibles (c)

     

    1,872

     

     

     

    1,872

     

     

     

    3,744

     

     

     

    3,744

     

    Other (f)

     

    485

     

     

     

    390

     

     

     

    472

     

     

     

    2,350

     

    Adjusted Operating Income

    $

    16,448

     

     

    $

    27,780

     

     

    $

    56,321

     

     

    $

    73,084

     

     

     

     

     

     

     

     

     

    Net income margin

     

    1.1

    %

     

     

    1.9

    %

     

     

    2.2

    %

     

     

    3.8

    %

    Adjusted Operating Margin

     

    3.1

    %

     

     

    5.5

    %

     

     

    5.2

    %

     

     

    7.0

    %

    Note: Percentages reflect line item as a percentage of net revenue, adjusted for rounding.

    Reconciliation of EBITDA and Adjusted EBITDA to Net Income

     

    Three Months Ended

     

    Six Months Ended

    In thousands

    July 1, 2023

     

    July 2, 2022

     

    July 1, 2023

     

    July 2, 2022

    Net income

    $

    5,614

     

     

    $

    9,734

     

     

    $

    23,884

     

     

    $

    39,881

     

    Interest expense (income), net

     

    1,836

     

     

     

    3,963

     

     

     

    6,703

     

     

     

    (181

    )

    Income tax provision

     

    275

     

     

     

    4,674

     

     

     

    10,450

     

     

     

    16,003

     

    Depreciation and amortization

     

    24,929

     

     

     

    25,245

     

     

     

    49,742

     

     

     

    50,396

     

    EBITDA

     

    32,654

     

     

     

    43,616

     

     

     

    90,779

     

     

     

    106,099

     

     

     

     

     

     

     

     

     

    Stock-based compensation expense (a)

     

    5,473

     

     

     

    3,638

     

     

     

    9,788

     

     

     

    7,372

     

    Asset impairment (b)

     

    893

     

     

     

    3,509

     

     

     

    1,280

     

     

     

    3,915

     

    Other (f)

     

    485

     

     

     

    390

     

     

     

    472

     

     

     

    2,350

     

    Adjusted EBITDA

    $

    39,505

     

     

    $

    51,153

     

     

    $

    102,319

     

     

    $

    119,736

     

     

     

     

     

     

     

     

     

    Net income margin

     

    1.1

    %

     

     

    1.9

    %

     

     

    2.2

    %

     

     

    3.8

    %

    Adjusted EBITDA Margin

     

    7.5

    %

     

     

    10.0

    %

     

     

    9.4

    %

     

     

    11.5

    %

    Note: Percentages reflect line item as a percentage of net revenue, adjusted for rounding.

    Reconciliation of Adjusted Diluted EPS to Diluted EPS

     

    Three Months Ended

     

    Six Months Ended

    Shares in thousands, except per share amounts

    July 1, 2023

     

    July 2, 2022

     

    July 1, 2023

     

    July 2, 2022

    Diluted EPS

    $

    0.07

     

     

    $

    0.12

     

     

    $

    0.30

     

     

    $

    0.47

     

    Stock-based compensation expense (a)

     

    0.07

     

     

     

    0.05

     

     

     

    0.12

     

     

     

    0.08

     

    Asset impairment (b)

     

    0.01

     

     

     

    0.04

     

     

     

    0.02

     

     

     

    0.04

     

    Amortization of acquisition intangibles (c)

     

    0.02

     

     

     

    0.02

     

     

     

    0.05

     

     

     

    0.04

     

    Amortization of debt discount and deferred financing costs (d)

     

    0.01

     

     

     

    0.01

     

     

     

    0.02

     

     

     

    0.01

     

    Losses (gains) on change in fair value of derivatives (e)

     

    0.00

     

     

     

    (0.01

    )

     

     

    0.04

     

     

     

    (0.11

    )

    Other (i)

     

    0.01

     

     

     

    0.00

     

     

     

    0.01

     

     

     

    0.02

     

    Tax expense (benefit) from stock-based compensation (g)

     

    0.00

     

     

     

    0.00

     

     

     

    0.01

     

     

     

    0.00

     

    Tax effect of total adjustments (h)

     

    (0.03

    )

     

     

    (0.03

    )

     

     

    (0.07

    )

     

     

    (0.02

    )

    Adjusted Diluted EPS

    $

    0.17

     

     

    $

    0.21

     

     

    $

    0.51

     

     

    $

    0.53

     

     

     

     

     

     

     

     

     

    Weighted average diluted shares outstanding

     

    78,343

     

     

     

    80,403

     

     

     

    78,784

     

     

     

    94,109

     

    Note: Some of the totals in the table above do not foot due to rounding differences.

    Reconciliation of Adjusted SG&A and Adjusted SG&A Percent of Net Revenue to SG&A

     

    Three Months Ended

     

    Six Months Ended

    In thousands

    July 1, 2023

     

    July 2, 2022

     

    July 1, 2023

     

    July 2, 2022

    SG&A

    $

    243,971

     

     

    $

    227,829

     

     

    $

    493,893

     

     

    $

    456,383

     

    Stock compensation expense (a)

     

    5,473

     

     

     

    3,638

     

     

     

    9,788

     

     

     

    7,372

     

    Other (j)

     

    489

     

     

     

    390

     

     

     

    476

     

     

     

    2,095

     

    Adjusted SG&A

    $

    238,009

     

     

    $

    223,801

     

     

    $

    483,629

     

     

    $

    446,916

     

     

     

     

     

     

     

     

     

    SG&A Percent of Net Revenue

     

    46.4

    %

     

     

    44.7

    %

     

     

    45.4

    %

     

     

    44.0

    %

    Adjusted SG&A Percent of Net Revenue

     

    45.3

    %

     

     

    43.9

    %

     

     

    44.5

    %

     

     

    43.1

    %

    Note: Percentages reflect line item as a percentage of net revenue.

    (a)

    Non-cash charges related to stock-based compensation programs, which vary from period to period depending on the timing of awards and performance vesting conditions.

    (b)

    Reflects write-off of primarily property, equipment and lease-related assets on closed or underperforming stores.

    (c)

    Amortization of the increase in carrying values of finite-lived intangible assets resulting from the application of purchase accounting following the acquisition of the Company by affiliates of KKR & Co. Inc.

    (d)

    Amortization of deferred financing costs and other non-cash charges related to our long-term debt. We adjust for amortization of deferred financing costs related to the 2025 Notes only when adjustment for these costs is not required in the calculation of diluted earnings per share under U.S. GAAP.

    (e)

    Reflects losses (gains) recognized in interest expense (income), net on change in fair value of de-designated hedges.

    (f)

    Other adjustments include amounts that management believes are not representative of our operating performance (amounts in brackets represent reductions in Adjusted Operating Income, Adjusted Diluted EPS and Adjusted EBITDA), which are primarily related to excess payroll taxes on vesting of restricted stock units and exercises of stock options, executive severance and relocation and other expenses and adjustments, including losses on other investments of $0.3 million for the six months ended July 2, 2022.

    (g)

    Tax expense (benefit) associated with accounting guidance requiring excess tax expense (benefit) related to vesting of restricted stock units and exercises of stock options to be recorded in earnings as discrete items in the reporting period in which they occur.

    (h)

    Represents the income tax effect of the total adjustments at our combined statutory federal and state income tax rates.

    (i)

    Reflects other expenses in (f) above, including debt issuance costs of $0.2 million for the three and six months ended July 1, 2023.

    (j)

    Reflects other expenses in (f) above, except for immaterial amounts for the three and six months ended July 1, 2023 and losses on other investments of $0.3 million for the six months ended July 2, 2022.

    Reconciliation of Adjusted Comparable Store Sales Growth to Total Comparable Store Sales Growth

     

    Comparable store sales growth (a)

     

    Three Months Ended July 1, 2023

     

    Three Months Ended July 2, 2022

     

    Six Months Ended July 1, 2023

     

    Six Months Ended July 2, 2022

     

    2023 Outlook (b)

    Owned & Host segment

     

     

     

     

     

     

     

     

     

    America's Best

    1.8 %

     

    (13.0) %

     

    1.8 %

     

    (10.1) %

     

     

    Eyeglass World

    (2.8) %

     

    (9.1) %

     

    (2.0) %

     

    (7.6) %

     

     

    Military

    (0.1) %

     

    (6.1) %

     

    1.6 %

     

    (5.1) %

     

     

    Fred Meyer

    (4.2) %

     

    (9.8) %

     

    (6.9) %

     

    (4.3) %

     

     

    Legacy segment

    0.5 %

     

    (12.9) %

     

    (1.5) %

     

    (8.6) %

     

     

     

     

     

     

     

     

     

     

     

     

    Total comparable store sales growth

    (0.1) %

     

    (11.0) %

     

    1.5 %

     

    (8.0) %

     

    0% - 3%

    Adjusted Comparable Store Sales Growth (b)

    1.0 %

     

    (12.4) %

     

    0.9 %

     

    (9.6) %

     

    0% - 3%

    (a) Total comparable store sales is calculated based on consolidated net revenue excluding the impact of (i) Corporate/Other segment net revenue, (ii) sales from stores opened less than 13 months, (iii) stores closed in the periods presented, (iv) sales from partial months of operation when stores do not open or close on the first day of the month and (v) if applicable, the impact of a 53rd week in a fiscal year. Brand-level comparable store sales growth is calculated based on cash basis revenues consistent with what the CODM reviews, and consistent with reportable segment revenues presented in Note 10. "Segment Reporting" in our unaudited condensed consolidated financial statements included in Part I. Item 1. in our Quarterly Report on Form 10-Q for the period ended July 1, 2023, with the exception of the Legacy segment, which is adjusted as noted in (b) (ii) below.

     

    (b) There are two differences between total comparable store sales growth based on consolidated net revenue and Adjusted Comparable Store Sales Growth: (i) Adjusted Comparable Store Sales Growth includes the effect of deferred and unearned revenue as if such revenues were earned at the point of sale, resulting in the following changes from total comparable store sales growth based on consolidated net revenue: an increase of 1.2% and a decrease of 1.2% for the three months ended July 1, 2023 and July 2, 2022, respectively, and a decrease of 0.4% and a decrease of 1.4% for the six months ended July 1, 2023 and July 2, 2022, respectively; and (ii) Adjusted Comparable Store Sales Growth includes retail sales to the Legacy partner's customers (rather than the revenues recognized consistent with the management & services agreement with the Legacy partner), resulting in the following changes from total comparable store sales growth based on consolidated net revenue: a decrease of 0.1% and a decrease of 0.2% for the three months ended July 1, 2023 and July 2, 2022, respectively, and a decrease of 0.2% and a decrease of 0.2% for the six months ended July 1, 2023 and July 2, 2022, respectively; (iii) with respect to the Company's 2023 Outlook, Adjusted Comparable Store Sales Growth includes an estimated 0.2% decrease for the effect of deferred and unearned revenue as if such revenues were earned at the point of sale and retail sales to the Legacy partner's customers (rather than the revenues recognized consistent with the management & services agreement).

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20230810997017/en/

    Get the next $EYE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EYE

    DatePrice TargetRatingAnalyst
    12/10/2025$32.00Buy
    Guggenheim
    7/30/2025$36.00Buy
    Roth Capital
    7/8/2025$30.00Equal Weight → Overweight
    Barclays
    5/9/2025$21.00Neutral → Buy
    Citigroup
    5/7/2025Underperform → Buy
    BofA Securities
    10/17/2023$25.00 → $16.00Buy → Neutral
    Goldman
    7/27/2023$28.00 → $22.00Buy → Neutral
    Citigroup
    7/27/2023$30.00 → $21.00Overweight → Equal Weight
    Wells Fargo
    More analyst ratings

    $EYE
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by National Vision Holdings Inc.

    SCHEDULE 13G/A - National Vision Holdings, Inc. (0001710155) (Subject)

    2/13/26 10:00:11 AM ET
    $EYE
    Ophthalmic Goods
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by National Vision Holdings Inc.

    SCHEDULE 13G/A - National Vision Holdings, Inc. (0001710155) (Subject)

    2/10/26 11:21:53 AM ET
    $EYE
    Ophthalmic Goods
    Health Care

    National Vision Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - National Vision Holdings, Inc. (0001710155) (Filer)

    12/16/25 4:30:58 PM ET
    $EYE
    Ophthalmic Goods
    Health Care

    $EYE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    National Vision Holdings, Inc. Announces Fourth Quarter and Fiscal 2025 Earnings Release and Conference Call

    National Vision Holdings, Inc. (NASDAQ:EYE) ("National Vision" or the "Company") will report its fourth quarter and fiscal 2025 financial results before the market opens on Wednesday, March 4, 2026, and will host a conference call at 8:30 a.m. Eastern Time. To pre-register for the conference call and obtain a dial-in number and passcode, please refer to the "Investors" section of the Company's website at https://ir.nationalvision.com. A live audio webcast of the conference call, together with related materials, will be available online in the "Investors" section of the Company's website. A replay of the audio webcast will be available shortly after the broadcast. About National Vision H

    2/18/26 7:00:00 AM ET
    $EYE
    Ophthalmic Goods
    Health Care

    National Vision Reaffirms Fiscal 2025 Outlook Ahead of Participation at the ICR Conference

    National Vision Holdings, Inc. (NASDAQ:EYE) ("National Vision" or the "Company") today reaffirmed its fiscal 2025 outlook ahead of its participation at the 2026 ICR Conference. The Company reaffirms its fiscal 2025 outlook for the 53 weeks ending January 3, 2026, as set forth below. New Stores: ~32 Adjusted Comparable Store Sales Growth(1)(2): 5.0% - 6.0% Net Revenue: $1.970 billion - $1.988 billion(3) Adjusted Operating Income(2)(3): $92 million - $98 million Adjusted Diluted EPS(2)(3)(4): $0.63 - $0.71 Depreciation and Amortization(5): $91 million - $93 million Interest(6): $17 million - $19 million Tax Rate(7): 28% Capital Expenditures: $80 million - $85 mill

    1/13/26 7:00:00 AM ET
    $EYE
    Ophthalmic Goods
    Health Care

    National Vision Announces Participation in the 2026 ICR Conference

    National Vision Holdings, Inc. (NASDAQ:EYE) ("National Vision" or the "Company") today announced that the Company is scheduled to present at the 2026 ICR Conference on Tuesday, January 13, 2026, at 9:00 a.m. Eastern Time. A live webcast of the presentation can be accessed in the "Investors" section of the Company's website at ir.nationalvision.com. The webcast will be archived and available on the website shortly after the event. About National Vision Holdings, Inc. National Vision Holdings, Inc. (NASDAQ:EYE) is one of the largest optical retail companies in the United States with over 1,200 stores in 38 states and Puerto Rico. With a mission of helping people by making quality eye ca

    1/6/26 4:05:00 PM ET
    $EYE
    Ophthalmic Goods
    Health Care

    $EYE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Guggenheim initiated coverage on National Vision with a new price target

    Guggenheim initiated coverage of National Vision with a rating of Buy and set a new price target of $32.00

    12/10/25 8:28:45 AM ET
    $EYE
    Ophthalmic Goods
    Health Care

    Roth Capital initiated coverage on National Vision with a new price target

    Roth Capital initiated coverage of National Vision with a rating of Buy and set a new price target of $36.00

    7/30/25 7:33:08 AM ET
    $EYE
    Ophthalmic Goods
    Health Care

    National Vision upgraded by Barclays with a new price target

    Barclays upgraded National Vision from Equal Weight to Overweight and set a new price target of $30.00

    7/8/25 8:23:14 AM ET
    $EYE
    Ophthalmic Goods
    Health Care

    $EYE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    General Manager Patel Priti V covered exercise/tax liability with 538 shares and converted options into 1,502 shares, increasing direct ownership by 7% to 13,869 units (SEC Form 4)

    4 - National Vision Holdings, Inc. (0001710155) (Issuer)

    10/6/25 4:44:22 PM ET
    $EYE
    Ophthalmic Goods
    Health Care

    Executive Chairman Fahs L Reade sold $301,278 worth of shares (12,600 units at $23.91), decreasing direct ownership by 2% to 532,195 units (SEC Form 4)

    4 - National Vision Holdings, Inc. (0001710155) (Issuer)

    9/17/25 4:11:52 PM ET
    $EYE
    Ophthalmic Goods
    Health Care

    SEC Form 4 filed by Chief Technology Officer Cutler David G

    4 - National Vision Holdings, Inc. (0001710155) (Issuer)

    9/9/25 4:23:22 PM ET
    $EYE
    Ophthalmic Goods
    Health Care

    $EYE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Peeler D Randolph bought $264,200 worth of shares (25,000 units at $10.57) (SEC Form 4)

    4 - National Vision Holdings, Inc. (0001710155) (Issuer)

    8/14/24 4:27:52 PM ET
    $EYE
    Ophthalmic Goods
    Health Care

    Director Hepner Virginia A bought $10,365 worth of shares (1,000 units at $10.37), increasing direct ownership by 3% to 36,635 units (SEC Form 4)

    4 - National Vision Holdings, Inc. (0001710155) (Issuer)

    8/14/24 4:26:51 PM ET
    $EYE
    Ophthalmic Goods
    Health Care

    Fahs L Reade bought $299,200 worth of shares (20,000 units at $14.96), increasing direct ownership by 3% to 633,097 units (SEC Form 4)

    4 - National Vision Holdings, Inc. (0001710155) (Issuer)

    5/14/24 8:01:46 AM ET
    $EYE
    Ophthalmic Goods
    Health Care

    $EYE
    Leadership Updates

    Live Leadership Updates

    View All

    National Vision, Inc. Unveils Bold New Brand Identity as Part of Strategic Transformation

    Brand refresh underscores National Vision's continued business evolution and unwavering commitment to accessible, high-quality eye care and eyewear DULUTH, Ga., Aug. 5, 2025 /PRNewswire/ -- National Vision Holdings, Inc. (NASDAQ:EYE), one of the largest optical retail companies in the United States, unveiled its new corporate brand identity, a major milestone in National Vision's transformation journey. The refreshed branding strengthens National Vision's position as a modern, agile and purpose-driven organization committed to helping people see their best to live their best. Experience the full interactive Multichannel News Release here: https://www.multivu.com/national-vision-holdings/934

    8/5/25 8:00:00 AM ET
    $EYE
    Ophthalmic Goods
    Health Care

    National Vision Appoints Alex Wilkes as CEO

    Reade Fahs to Assume Executive Chairman Position Transition Effective August 1, 2025 National Vision Holdings, Inc. (NASDAQ:EYE) ("National Vision" or the "Company") today announced that its Board of Directors has appointed Alex Wilkes as the Company's next Chief Executive Officer, effective August 1, 2025, and he will join the Company's Board at that time. Mr. Wilkes succeeds Reade Fahs who will assume the role of Executive Chairman of the Board. Mr. Fahs will continue to work closely with Mr. Wilkes, ensuring a smooth transition. "National Vision has been on a journey of significant transformation for the past few years, and today I am pleased to announce the next chapter in that tran

    4/29/25 6:00:00 AM ET
    $EYE
    Ophthalmic Goods
    Health Care

    National Vision Appoints Jim McGrann and Michael Nicholson to Board of Directors

    Enters into Cooperation Agreement with Engine Capital National Vision Holdings, Inc. (NASDAQ:EYE) ("National Vision" or the "Company") today announced the appointment of two new independent directors, Jim McGrann and Michael Nicholson to its Board of Directors (the "Board"), effective March 17, 2025. Mr. McGrann will serve on the Board's Compensation Committee and Mr. Nicholson will serve on the Board's Audit Committee and Nominating and Corporate Governance Committee. With the addition of Messrs. McGrann and Nicholson, the Board will expand from 9 to 11 members. The Board has also formed an Advisory Committee that will help oversee National Vision's ongoing transformation initiatives with

    3/17/25 4:05:00 PM ET
    $EYE
    Ophthalmic Goods
    Health Care

    $EYE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by National Vision Holdings Inc.

    SC 13G/A - National Vision Holdings, Inc. (0001710155) (Subject)

    11/14/24 12:33:08 PM ET
    $EYE
    Ophthalmic Goods
    Health Care

    Amendment: SEC Form SC 13G/A filed by National Vision Holdings Inc.

    SC 13G/A - National Vision Holdings, Inc. (0001710155) (Subject)

    11/12/24 4:45:48 PM ET
    $EYE
    Ophthalmic Goods
    Health Care

    Amendment: SEC Form SC 13G/A filed by National Vision Holdings Inc.

    SC 13G/A - National Vision Holdings, Inc. (0001710155) (Subject)

    11/4/24 1:18:26 PM ET
    $EYE
    Ophthalmic Goods
    Health Care

    $EYE
    Financials

    Live finance-specific insights

    View All

    National Vision Holdings, Inc. Announces Fourth Quarter and Fiscal 2025 Earnings Release and Conference Call

    National Vision Holdings, Inc. (NASDAQ:EYE) ("National Vision" or the "Company") will report its fourth quarter and fiscal 2025 financial results before the market opens on Wednesday, March 4, 2026, and will host a conference call at 8:30 a.m. Eastern Time. To pre-register for the conference call and obtain a dial-in number and passcode, please refer to the "Investors" section of the Company's website at https://ir.nationalvision.com. A live audio webcast of the conference call, together with related materials, will be available online in the "Investors" section of the Company's website. A replay of the audio webcast will be available shortly after the broadcast. About National Vision H

    2/18/26 7:00:00 AM ET
    $EYE
    Ophthalmic Goods
    Health Care

    National Vision Holdings, Inc. Reports Third Quarter 2025 Financial Results

    Transformation Initiatives Continue to Drive Strong Performance Raises Fiscal 2025 Outlook Third quarter 2025 highlights compared to third quarter 2024: Net revenue from continuing operations increased 7.9% to $487.3 million Comparable store sales growth of 6.8% and Adjusted Comparable Store Sales Growth of 7.7% represented the 11th consecutive quarter of positive growth Income from continuing operations of $3.4 million, Diluted EPS from continuing operations of $0.04, with Income (loss) from continuing operations margin improving to 0.7% from (1.9)% Adjusted Operating Income from continuing operations of $19.8 million, up 38.6%, with Adjusted Operating Margin improving to 4.1% fro

    11/5/25 6:00:00 AM ET
    $EYE
    Ophthalmic Goods
    Health Care

    National Vision Holdings, Inc. Announces Third Quarter 2025 Earnings Release and Conference Call

    National Vision Holdings, Inc. (NASDAQ:EYE) ("National Vision" or the "Company") will report its third quarter 2025 financial results before the market opens on Wednesday, November 5, 2025, and will host a conference call at 8:30 a.m. Eastern Time. To pre-register for the conference call and obtain a dial-in number and passcode, please refer to the "Investors" section of the Company's website at https://ir.nationalvision.com. A live audio webcast of the conference call, together with related materials, will be available online in the "Investors" section of the Company's website. A replay of the audio webcast will be available shortly after the broadcast. About National Vision Holdings,

    10/22/25 8:00:00 AM ET
    $EYE
    Ophthalmic Goods
    Health Care